Dassault Systèmes and Medidata Solutions To Join Forces To Accelerate the Life Sciences Industry Innovation for Patient-Centric Experience Through End-to-End Collaborative Platform

Medidata Solutions’ market-leading clinical cloud solutions are used by 1,300 customers worldwide to develop their therapeutic innovations and clinical operations performance •Scientific modeling, simulation and digital assets of worldwide trials knowledge and know-how combine to accelerate developments in personalized health, for the benefit of the patient •Life Sciences industry will also benefit from the platform effect spanning... Read more

Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)

Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC) PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA® (pembrolizumab) SANTA CLARA, Calif., June 11, 2019 Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration... Read more

Water Leaders Chart the Digital Transformation Journey for Utilities

International Water Association (IWA) and Xylem White Paper Maps Digital Adoption Trends and Identifies Key Learnings to Help Drive Migration Publication harnesses insights from 40 utilities and over 20 industry thought leaders globally New Digital Water Adoption Curve enables utilities to chart their progress on the digital transformation journey; report urges water leaders to think... Read more

FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma

Basel, 11 June 2019 FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of... Read more

Xylem’s new ‘Decision Intelligence’ paper presents six comprehensive strategies to transform the economics of utility water management

New Xylem publication discusses how decision intelligence enables utilities to secure a sustainable, resilient and affordable water future DENVER–(BUSINESS WIRE)–Jun. 10, 2019– As global water challenges intensify, new approaches are needed to create a step change improvement in water system performance. Today at ACE19, global water technology company, Xylem (NYSE: XYL) unveiled a new publication... Read more

Fernando Vergas appointed new Vice President of WITec Instruments Corporation

WITec GmbH, leading manufacturer of Raman and scanning-probe microscopes, has named Dr. Fernando Vargas as Vice President of WITec Instruments Corporation, its USA-based subsidiary, and Area Manager of the USA market. As a longtime WITec team member with a background in physics, Vargas has extensive experience in both the scientific application and strategic sales of... Read more

QIAGEN launches first FDA-approved companion diagnostic for PIK3CA biomarkers to enhance precision medicine in breast cancer

Germantown, Maryland, and Hilden, Germany, May 24, 2019 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the immediate launch of its therascreen® PIK3CA RGQ PCR Kit (therascreen PIK3CA Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in identifying breast cancer patients eligible for treatment with PIQRAY (alpelisib), a... Read more

QIAGEN gains 510(k) clearance by FDA for QIAstat-Dx in the U.S. and launches system as next generation platform for syndromic insights

Germantown, Maryland, and Hilden, Germany, May 20, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of its QIAstat-Dx syndromic testing system after receiving 510(k) clearance by the U.S. Food and Drug Administration, along with the multiplex QIAstat-Dx® Respiratory Panel for simultaneous qualitative detection and identification of multiple respiratory... Read more

Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia

Basel, 16 May 2019 Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta offers more adults with chronic lymphocytic leukaemia... Read more

New Study Demonstrates Clinical Utility of Liquid Biopsy for Cancer Monitoring

Multi-institutional clinical research indicates liquid biopsy can detect changes in tumor profile and resistance to treatment CARLSBAD, Calif., May 15, 2019 /PRNewswire/ — Growing scientific evidence supports liquid biopsy as a valuable tool for monitoring treatment response in patients with cancer. A new retrospective clinical research study showing comparable results between liquid and tissue biopsy in... Read more